Children’s Minnesota has backed the first close of 4Bio Ventures II, a $150m venture fund that will focus on areas such as cell and gene therapy.
UK-based investment firm 4Bio Capital achieved a first close of $50m for its second venture capital fund on Monday with a commitment from paediatric healthcare provider Children’s Minnesota.
The other limited partners in 4Bio Ventures II have not been identified. 4Bio Capital is targeting a $150m final close by the second half of 2020.
4Bio focuses exclusively on early-stage developers of advanced therapies in areas of high unmet medical need, such as cell and gene therapy, RNA-based therapy and the…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
